The results show that known predictive markers have no value in meningiomas, and the lack of EGFR and downstream protein mutations may partially explain the results of the clinical trials with the anti-EGFR inhibitors, erlotinib and gefitinib (10). The gene discussed is EGFR; the disease is meningioma.